[go: up one dir, main page]

DE3686019D1 - Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten. - Google Patents

Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.

Info

Publication number
DE3686019D1
DE3686019D1 DE8686201789T DE3686019T DE3686019D1 DE 3686019 D1 DE3686019 D1 DE 3686019D1 DE 8686201789 T DE8686201789 T DE 8686201789T DE 3686019 T DE3686019 T DE 3686019T DE 3686019 D1 DE3686019 D1 DE 3686019D1
Authority
DE
Germany
Prior art keywords
stomestonal
nitrofurantoin
diseases
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686201789T
Other languages
English (en)
Other versions
DE3686019T2 (de
Inventor
William Gerald Kraft
Donna Rene Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Pharmaceuticals Inc
Original Assignee
Norwich Eaton Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwich Eaton Pharmaceuticals Inc filed Critical Norwich Eaton Pharmaceuticals Inc
Application granted granted Critical
Publication of DE3686019D1 publication Critical patent/DE3686019D1/de
Publication of DE3686019T2 publication Critical patent/DE3686019T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE8686201789T 1985-10-24 1986-10-15 Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten. Expired - Fee Related DE3686019T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/790,919 US4959384A (en) 1985-10-24 1985-10-24 Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders

Publications (2)

Publication Number Publication Date
DE3686019D1 true DE3686019D1 (de) 1992-08-20
DE3686019T2 DE3686019T2 (de) 1993-01-07

Family

ID=25152123

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686201789T Expired - Fee Related DE3686019T2 (de) 1985-10-24 1986-10-15 Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.

Country Status (6)

Country Link
US (1) US4959384A (de)
EP (1) EP0219912B1 (de)
JP (1) JP2669818B2 (de)
DE (1) DE3686019T2 (de)
IE (1) IE59739B1 (de)
PH (1) PH21421A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US5178880A (en) * 1989-07-25 1993-01-12 Norwich Eaton Pharmaceuticals, Inc. Liquid suspensions of nitrofurantoin
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
WO1995008332A1 (en) * 1993-09-20 1995-03-30 The Procter & Gamble Company Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
US6521270B1 (en) * 2001-06-11 2003-02-18 The Procter & Gamble Company Compositions comprising nitrofurantoin and uva ursi
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
EP1563084A4 (de) * 2002-11-08 2006-03-01 Hematech Llc Transgene ungulaten mit reduzierter prionproteinaktivität und verwendungen davon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462631B1 (de) * 1985-06-13 1996-03-20 Barry James Dr. Marshall Verfahren und Zusammensetzungen zur Behandlung von gastrointestinalen Störungen

Also Published As

Publication number Publication date
EP0219912A2 (de) 1987-04-29
EP0219912A3 (en) 1989-07-26
JP2669818B2 (ja) 1997-10-29
EP0219912B1 (de) 1992-07-15
IE862800L (en) 1987-04-24
IE59739B1 (en) 1994-03-23
DE3686019T2 (de) 1993-01-07
PH21421A (en) 1987-10-15
JPS62161726A (ja) 1987-07-17
US4959384A (en) 1990-09-25

Similar Documents

Publication Publication Date Title
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
ATE131068T1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE3583392D1 (de) Carbonatapatit enthaltendes mittel und die verwendung von carbonatapatit fuer implantate.
ATE384703T1 (de) Piperazinyl-substituierte phenylpyrimidinderivative zur behandlung oder vorbeugung von zns erkrankungen
ATE31670T1 (de) Verfahren zur behandlung von verpackungsmaterial und das dementsprechend behandelte material.
DE3688296D1 (de) Arzneimittel zur behandlung von erbrechen.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
DE3583220D1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
DE3782028D1 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DE3781574D1 (de) Calixaren-derivate und die verwendung dieser verbindungen zur sequestrierung von metallen.
DE3686019D1 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
DE3687692D1 (de) Geschlechtshormone zur behandlung von immun-mangel-krankheiten.
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE3679781D1 (de) Verwendung von zusammensetzungen fuer die behandlung und die prophylaxe von epithelialer zerstoerung.
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
AT383142B (de) Vorrichtung zur kultivierung und behandlung von biokatalysatoren
DE3686688D1 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
ATE136463T1 (de) Verwendung von 1,2,3,4-tetrahydroacridinen zur behandlung von aids, sowie verbindungen
DE3688414D1 (de) Verwendung von chinolinderivaten zur herstellung von medikamenten zur behandlung von zerebralen gefaesskrankheiten und zerebraler senilitaet.
DE3881377D1 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
DE69103294D1 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PROCTER & GAMBLE PHARMACEUTICALS, NORWICH, N.Y., U

8339 Ceased/non-payment of the annual fee